Home / Stocks / MDLN

Medline (MDLN, Health Care Supplies) Stock Valuation & Fair Value Trading above fair value

Medline (MDLN, Health Care Supplies) trades at a blended P/E of 21.5, about 27% below its historical normal valuation, with a forward growth estimate of 8.2% and a PEG of 2.63. Priced at its historical normal P/E of 29.4 on the same blended earnings, the 2026-09-18 close of $31.64 corresponds to about $43.20 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
21.5
Normal P/E
29.4
PEG
2.63
Fwd growth
8.2%
Div yield
0.0%
RSI (14)
36.5
Neutral

Valuation flags

Verdict history

tickerseer's rating moved from significantly overvalued (2026-07-31) to trading above fair value (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 26.4 to 21.5 between 2026-07-31 and 2026-09-21, against a normal P/E of 29.4, with 1 rating change over 18 recorded weeks.2026-07-31: P/E 26.4, Significantly overvalued (recalculated)2026-08-03: P/E 26.6, Significantly overvalued2026-08-07: P/E 26.6, Significantly overvalued (recalculated)2026-08-10: P/E 23.8, Significantly overvalued2026-08-14: P/E 23.8, Significantly overvalued (recalculated)2026-08-17: P/E 24.1, Significantly overvalued2026-08-21: P/E 24.1, Significantly overvalued (recalculated)2026-08-24: P/E 23.4, Significantly overvalued2026-08-27: P/E 23.4, Significantly overvalued (recalculated)2026-08-28: P/E 23.4, Significantly overvalued (recalculated)2026-08-30: P/E 23.4, Significantly overvalued (recalculated)2026-08-31: P/E 24.1, Significantly overvalued2026-09-05: P/E 24.1, Significantly overvalued (recalculated)2026-09-07: P/E 24.8, Significantly overvalued2026-09-12: P/E 24.8, Significantly overvalued (recalculated)2026-09-14: P/E 22.1, Trading above fair value2026-09-19: P/E 22.1, Trading above fair value (recalculated)2026-09-21: P/E 21.5, Trading above fair value22.024.026.028.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 29.4
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 26.4-10%Significantly overvalued
2026-08-03P/E 26.6-10%Significantly overvalued
2026-09-14P/E 22.1-25%Trading above fair value
2026-09-21P/E 21.5-27%Trading above fair value ← now

Frequently asked questions

Is Medline stock overvalued?

At a blended P/E of 21.5 versus its historical normal P/E of 29.4, Medline trades about 27% below its typical valuation, with a PEG of 2.63 on 8.2% forward growth. tickerseer currently rates it trading above fair value.

What is Medline's fair value and PEG?

Medline trades at a blended P/E of 21.5 against a historical normal P/E of 29.4, a PEG of 2.63, and a forward growth estimate of 8.2%. Priced at its historical normal P/E of 29.4 on the same blended earnings, the 2026-09-18 close of $31.64 corresponds to about $43.20 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Medline changed?

tickerseer's rating moved from significantly overvalued (2026-07-31) to trading above fair value (2026-09-21).

Industry: Health Care Supplies. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track MDLN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.